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Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen 
Mary University of London, London, UK
Adrenal insufficiency is a rare, but potentially fatal medical condition. In children, the 
cause is most commonly congenital and in recent years a growing number of causative 
gene mutations have been identified resulting in a myriad of syndromes that share adre-
nal insufficiency as one of the main characteristics. The evolution of adrenal insufficiency 
is dependent on the variant and the particular gene affected, meaning that rapid and 
accurate diagnosis is imperative for effective treatment of the patient. Common practice 
is for candidate genes to be sequenced individually, which is a time-consuming process 
and complicated by overlapping clinical phenotypes. However, with the availability, and 
increasing cost effectiveness of whole-exome sequencing, there is the potential for this to 
become a powerful diagnostic tool. Here, we report the results of whole-exome sequenc-
ing of 43 patients referred to us with a diagnosis of familial glucocorticoid deficiency 
(FGD) who were mutation negative for MC2R, MRAP, and STAR the most commonly 
mutated genes in FGD. WES provided a rapid genetic diagnosis in 17/43 sequenced 
patients, for the remaining 60% the gene defect may be within intronic/regulatory regions 
not covered by WES or may be in gene(s) representing novel etiologies. The diagnosis of 
isolated or familial glucocorticoid deficiency was only confirmed in 3 of the 17 patients, 
other genetic diagnoses were adrenal hypo- and hyperplasia, Triple A, and autoimmune 
polyendocrinopathy syndrome type I, emphasizing both the difficulty of phenotypically 
distinguishing between disorders of PAI and the utility of WES as a tool to achieve this.
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introduction
The hypothalamic–pituitary–adrenal (HPA) axis is essential in the physiological response to stress 
and illness. Such external stimuli trigger the production of ACTH from corticotroph cells in the ante-
rior pituitary, under the control of hypothalamic CRH and AVP, which acts on the ACTH receptor 
[also known as MC2R] on the surface of adrenal cells to elicit the production of glucocorticoids (1). 
Abbreviations: AHC, adrenal hypoplasia congenital; AI, adrenal insufficiency; APECED/APS1, autoimmune polyendocrinop-
athy-candidiasis-ectodermal dystrophy/autoimmune polyendocrinopathy syndrome type I; CAH, congenital adrenal hypo-
plasia; FGD, familial glucocorticoid deficiency; HGMD, The Human Gene Mutation Database; IMAGE, IUGR, metaphyseal 
dysplasia, genital anomalies; IUGR, intrauterine growth retardation; IVA, Ingenuity variant analysis; LCAH, lipoid congenital 
adrenal hypoplasia; MAF, minor allele frequency; N/A, not applicable; NK, natural killer; OMIM, online Mendelian inheritance 
in man; PAI, primary adrenal insufficiency; X-ALD, X-linked adrenoleukodystrophy.
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The adrenal gland is composed of a medulla which secretes 
catecholamines and a cortex which comprises three layers: the 
zona glomerulosa which produces mineralocorticoids, the zona 
fasciculata which produces glucocorticoids (cortisol in humans), 
and the zona reticularis which produces adrenal androgens. 
Adrenal insufficiency is a serious medical condition that is invari-
ably fatal unless diagnosed and treated early. Adrenal insufficiency 
is classified into primary, direct impairment of the adrenal gland 
to secrete cortisol, or secondary, impaired ACTH secretion from 
the pituitary gland. Primary adrenal insufficiency (PAI) can be 
acquired or congenital, the acquired group including infectious, 
traumatic, or drug-induced causes. Congenital PAI encompasses 
disorders such as congenital adrenal hyperplasia (CAH) (2–4), 
familial glucocorticoid deficiency (FGD) (5), and autoimmune 
polyglandular syndrome type I (APS-1) (6) as well as many others 
(listed in Table 1).
Children with PAI present with signs and symptoms resulting 
from low serum cortisol (such as failure to thrive, hypoglycemia, 
and lethargy) and from high plasma ACTH levels (hyperpigmen-
tation – which is variable and can be dependent on ethnic origin/
MC1R status). Biochemical analysis in cases of PAI will often 
reveal a low morning serum cortisol concentration (<80 nmol/l) 
paired with elevated plasma ACTH levels (>45 pmol/l), due to lack 
of negative feedback (7, 8). Such biochemical indicators change 
depending on the clinical scenario, for example, cortisol meas-
urements maybe within normal range but inappropriately low for 
TaBle 1 | list of disorders and gene mutations identified with primary adrenal insufficiency (Pai) as a core characteristic.
gene name and symbol Disorder OMiM number extra adrenal manifestation no of exons
21-Hydroxylase (CYP21A2) CAH 201910 Ambiguous genitalia, hirsutism 10
11-B Hydroxylase (CYP11B1) CAH 202010 Ambiguous genitalia, hypertension 9
17-a hydroxylase (CYP17A1) CAH 202110 Ambiguous genitalia, hypertension, delayed puberty 8
Nuclear receptor subfamily 5A1 (NR5A1) AI 184757 Gonadal dysgenesis, XY sex reversal 7
Nuclear receptor subfamily 0B 1 (NR0B1) AHC 300200 Hypogonadotrophic hypogonadism in males  
(Duchenne muscular dystrophy, glycerol deficiency  
if part of Xp21 deletion)
2
P450 (cytochrome) oxidoreductase (POR) CAH 201750 Antley-Bixler syndrome with genital anomalies 15
3-beta hydroxysteroid dehydrogenase (HSD3B2) CAH 201810 Ambiguous genitalia 4
Cytochrome P450 11A1 (CYP11A1) AI 613743 XY sex reversal 9
Steroidogenic acute regulatory protein (STAR) LCAH/FGD 201710/609197 XY sex reversal 7
Alacrima achalasia adrenal (AAAS) Triple A 231550 Alacrima, achalasia, deafness, cognitive impairment, 
hyperkeratosis 
16
Autoimmune regulator (AIRE) APECED/APS1 240300 Hypoparathyroidism, immune deficiency 14
Cyclin-dependent kinase inhibitor 1C (CDKN1C) IMAGE 614732 IUGR, metaphyseal dysplasia, genital anomalies 3
ATP-binding cassette, sub-family D, member 1 
(ABCD1)
X-ALD 300100 Muscle weakness, cognitive degeneration, blindness, 
spasticity, quadriparesis
11
Melanocortin 2 receptor (MC2R) FGD 202200 N/A 1
MC2R accessory protein (MRAP) FGD 607398 N/A 4
Mini chromosome maintenance deficient (MCM4) FGD 609981 NK cell deficiency, short stature, chromosomal instability 22
Nicotinamide nucleotide transhydrogenase (NNT) FGD 614736 N/A 22
Thioredoxin reductase 2 (TXNRD2) FGD - N/A 7
Glutathione peroxidase 1 (GPX1) FGD - N/A 2
Peroxiredoxin 3 (PRDX3) FGD - N/A 7
Key: OMIM, online Mendelian inheritance in man; CAH, congenital adrenal hyperplasia; AI, adrenal insufficiency; AHC, adrenal hypoplasia congenital; LCAH, lipoid congenital adrenal 
hyperplasia; FGD, familial glucocorticoid deficiency; APECED/APS1, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy/autoimmune polyendocrinopathy syndrome 
type I; IMAGE, IUGR, metaphyseal dysplasia, genital anomalies; X-ALD, X-linked Adrenoleukodystrophy; IUGR, intrauterine growth retardation; NK, natural killer; N/A, not applicable.
the given situation, for example during sepsis (9). Measurement 
of urea and electrolytes, plasma renin activity or concentration, 
and aldosterone concentration will determine the presence of 
mineralocorticoid deficiency. An ACTH stimulation test is often 
undertaken in cases of suspected adrenal insufficiency, where a 
synthetic form of ACTH, (ACTH [1–24], Synacthen), is admin-
istered and plasma cortisol measured 30 and 60 min later. PAI is 
excluded if serum cortisol concentrations are above 500 nmol/l 
following 250 μg of Synacthen administered IV or IM (10).
Many of the genetic disorders listed in Table 1 may present with 
PAI. Some of these conditions will have additional features and 
investigations will reveal abnormal findings, for example, adrenal 
cortex auto-antibodies or perturbed levels of 17-hydroxyproges-
terone and very-long chain fatty acids to name a few [reviewed 
in Ref. (8)]. However, with recent discoveries of new genes and 
novel mutations in known genes causing PAI, it is becoming 
increasingly clear that considerable phenotypic overlap between 
genetic disorders occurs. This is applicable to the condition FGD, 
once thought to be fairly distinct from other causes of PAI (see 
Figure 1). FGD patients present with isolated glucocorticoid defi-
ciency and normal mineralocorticoid production. Biochemical 
results in FGD point toward ACTH resistance, with serum corti-
sol often undetectable and extremely high plasma ACTH (11). As 
we learn more about the genetic causes of FGD, the boundaries 
between different PAI disorders or diagnostic features of FGD are 
being challenged (12–20).
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Similar to many other endocrine disorders, obtaining an 
accurate diagnosis and understanding of the underlying pathol-
ogy is essential for the management and treatment of the patient. 
Obtaining a genetic diagnosis will also enable prenatal screening, 
which in the case of CAH may inform or remove the need for 
antenatal treatment (21). Furthermore, a genetic diagnosis may 
directly alter therapeutic management of the patient removing 
the need for unnecessary medications lifelong (12).
In children, CAH is the commonest cause of PAI, causing 
71.8% of cases in one report (22). In the cohort studied by Perry 
et al., this was followed by autoimmune causes (12.7%), adreno-
leukodystrophy (3.9%), syndromic causes (4.9%), X-linked AHC 
(1%), and several were unexplained (5.8%). In this study, five 
international groups were involved in the mutational analysis of 
the various genes implicated in PAI (22).
Exome sequencing provides a robust technique by which 
coding variants can be identified and matched with their associ-
ated disease and complex phenotype (23). Exome sequencing 
was first used to identify the rare genetic mutation implicated 
in Miller Syndrome (23) and has been successfully used where 
linkage analysis has proven inadequate due to the rarity of the 
disease being investigated, the sporadic nature of the disease 
being investigated, or uninformative pedigrees. In addition, 
the MLL2 mutation was identified using exome sequencing as 
a cause of Kabuki syndrome, a rare genetic disorder. The causa-
tive genetic variant leading to Kabuki syndrome had proved 
difficult to determine due to the rarity of the disease, there 
only being approximately 400 cases worldwide (24). Further 
FigUre 1 | Pie chart indicating the percentage of FgD cases due to 
gene mutations in the Melanocortin 2 receptor (MC2R), Mc2r 
accessory protein (MRAP), Mini chromosome maintenance deficient 
4 (MCM4), nicotinamide nucleotide transhydrogenase (NNT), 
steroidogenic acute regulatory protein (sTar), cytochrome p450 
11a1 (cYP11a1), Thioredoxin reductase 2 (TXNRD2), glutathione 
peroxidase 1 (GPX1), and Peroxiredoxin 3 (PRDX3) in our patient 
cohort.
success in disease gene identification through WES includes the 
identification of the missense variant in SLC26A3 which results 
in congenital chloride diarrhea (25). In addition to using exome 
sequencing to identify a link between variants and disease, it has 
potential to be used as a diagnostic tool. In the case of congenital 
chloride diarrhea, exome sequencing identified the SLC26A3 
variant, and future diagnosis of this condition could be achieved 
through exome sequencing (25). Even in cases demonstrating 
identification of disease causing variants using whole-genome 
sequencing, as in the case of hypercholesterolemia, these could 
often have been identified by exome sequencing (26). Many 
more examples, illustrating the emerging importance of exome 
sequencing, are summarized by Gilissen et  al. (27). In PAI, 
similar to many other disorders, WES is often cheaper than the 
sequencing of all known candidate genes. Furthermore, given 
the lower cost associated with exome sequencing relative to 
whole-genome sequencing, WES sequencing may provide a 
robust and cost-effective screening and diagnostic tool for rare 
genetic conditions.
We have a cohort of >300 patients with FGD, 60% of them 
have a genetic diagnosis. We have previously used targeted and 
WES to identify novel causes of FGD in this collection (17, 
18, 28). WES of a subset of our unsolved cases allowed for the 
screening of variants known to cause FGD as well as the pos-
sibility of discovering novel causative genes for PAI. Using PAI 
as an example, this paper offers a valuable commentary on the 
use of WES as a diagnostic tool in cases where the number of 
causative genes makes targeted gene sequencing more expensive 
than WES.
subject and Methods
sequencing of candidate genes in Familial 
glucocorticoid Deficiency
Patient genomic DNA was extracted from blood leukocytes. PCR 
was used to amplify regions of candidate genes implicated in 
FGD. All patients were screened for mutations in Melanocortin-
2-receptor (MC2R), Melanocortin-2-receptor accessory protein 
(MRAP), and steroidogenic acute regulatory protein (STAR), the 
most commonly mutated genes in FGD, accounting for 50% of 
cases (Figure 1). Most patients underwent additional screening 
for mutations in nicotinamide nucleotide transhydrogenase 
(NNT), a recently discovered FGD causal gene (primer sequences 
available on request). After initial denaturation of template DNA 
at 95oC for 5  min, a touchdown thermal cycling program was 
used; 10 cycles of 95oC for 30 s, 65oC for the first cycle, this was 
then decreased by 1oC for each subsequent cycle for 10 cycles, 
and then 72oC for 1  min. This was then followed by 25 cycles 
of 95oC for 30 s, 55oC for 30 s and 72oC for 1 min. After the last 
cycle, there is an extension step at 72oC for 5 min. PCR products 
were sequenced using ABI Prism Big Dye Sequencing kit and 
an ABI 377 automated DNA sequencer (Applied Biosystems) as 
described in the manufacturer’s instructions.
Informed consent was obtained from affected individuals and/
or their parents. Ethical approval for the study was obtained from 
the Outer North East London Research Ethics Committee, refer-
ence number 09/H0701/12.
FigUre 2 | Filtration strategy to screen variants from Wes data.
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exome sequencing
Whole-exome sequencing (WES) was performed on 43 patients 
with a diagnosis of FGD who were negative on screening for can-
didate genes (described above). This included many ‘cold cases’ 
referred to us as isolated glucocorticoid deficiency. In addition, 
one sibling (of patient 9) was sequenced for the causative gene 
and family members underwent Sanger sequencing of candidate 
variants to determine segregation.
Exome sequencing was performed using the Agilent 
SureSelect all exon V4 capture and paired-end (2  ×  100) 
sequencing on an Illumina HiSeq 2000 at Otogenetics (Norcross, 
GA). First analysis pipeline: initially sequencing read alignment, 
variant calling, and annotation were performed by DNAnexus 
(DNAnexus Inc.1, Mountain View, CA, USA), their Nucleotide-
Level Variation analysis outputs were then screened with our list 
of genes via the DNAnexus Classic platform which permitted 
variants table viewing and filtering functionality. This platform 
no longer exists and more recently these data were reanalyzed 
uploading the vcf files to Ingenuity variant analysis2. Second 
analysis pipeline: the raw data were also reanalyzed, aligning 
to the H. Sapiens GRCh37–b37 (1000genomes Phase 1) refer-
ence genome with BWA-MEM FastQ Readmapper VCF files, 
generated by Vendor Human Exome GATK-Lite Variant Caller 
(Unified Genotyper) and uploaded to Ingenuity variant analysis. 
1 www.dnanexus.com
2 www.ingenuity.com
Single Nucleotide Polymorphisms, with threshold coverage of at 
least 10 reads on the respective nucleotide, were included in the 
analysis. The variant files from both analyses were screened for 
causal variants using Ingenuity variant analysis with the filtering 
strategy outlined in Figure 2. Sequence changes in PAI causal 
genes were confirmed by PCR designed to cover the affected 
region followed by Sanger sequencing (primer sequences avail-
able on request).
results
Mean target coverage across the exomes varied from 
52.34 – 62.52X and > 90% of target bases were covered 10X. For 
both analysis pipelines, similar numbers of variants were called 
from 43 exomes combined, after confidence filtration the first 
analysis pipeline produced a total of 393,015 variants in 20,327 
genes with many variants being common between samples 
whereas the second had 393,262 variants in 20,249 genes. 400 
and 358 variants within our 20 PAI genes (Table 1) were called by 
first and second pipelines, respectively, and after further filtration 
(Figure 2) the following results were obtained. To be as inclusive 
as possible, data from the first analysis pipeline are detailed below 
except where stated (Tables 2 and 3).
Positive genetic Diagnosis
After Ingenuity filtration screening (Figure  2) of the 20 PAI 
causal genes listed in Table 1, 51 variants in 12 genes remained 
(Table  2), with no variants in ABCD1, CDKN1C, CYP17A1, 
TaBle 2 | non-synonymous variants detected after ingenuity filtration screening of the 20 Pai causal genes listed in Table 1.
Patient 
number
chromosome Position 
(genome 
assembly: 
grch37.
p13)
reference 
allele
sample 
allele
Variation 
type
gene 
region
gene symbol Protein variant Translation 
impact
siFT  
function 
prediction
dbsnP iD/
hgMD 
reference 
(where 
annotated)
nhlBi esP 
frequency 
(%)
Zygosity causality
1 X 30326991 C A SNV Exonic NR0B1 E164* Stop gain 0 Hemi Causal
2 X 30326498 G Insertion Exonic NR0B1 G329fs*60 Frameshift 0 Hemi Causal
3 X 30326727 G A SNV Exonic NR0B1 Q252* Stop gain 0 Hemi Causal
4 X 30326343 A Insertion Exonic NR0B1 Y380fs*9 Frameshift 0 Hemi Causal
5 15 74631631 G T SNV Exonic CYP11A1 Q395K Missense Damaging 0 Het Causal in comp het
5 15 74640307 G A SNV Exonic CYP11A1 R120Q Missense Damaging 0 Causal in comp het
6 15 74635318 C T SNV Exonic CYP11A1 T330T Synonymous Splicing 0 Het Causal in comp het
6 15 74635368 C T SNV Exonic CYP11A1 E314K Missense Tolerated rs6161 0.28 Het Causal in comp het
7 15 74630315 A T SNV Exonic CYP11A1 *122Rext*68 Stop loss Damaging 0 Causal in comp het
7 15 74635473 T Deletion Exonic CYP11A1 I279Yfs*9 Frameshift Damaging CD050132 0 Causal in comp het
8 15 74630315 A T SNV Exonic CYP11A1 *122Rext*68 Stop loss Damaging 0 Causal in comp het
8 15 74635473 T Deletion Exonic CYP11A1 I279Yfs*9 Frameshift Damaging CD050132 0 Causal in comp het
9 15 74632009 G A SNV Exonic CYP11A1 A359V Missense Damaging rs121912812 0 Homo Causal homozygous
10 5 43613069 C T SNV Exonic NNT R71* Stop gain Damaging 0 Het Causal in comp het 
with pseudoexon 
event not detected 
by WES
11 5 43613069 C T SNV Exonic NNT R71* Stop gain Damaging 0 Het Causal in comp het 
with pseudoexon 
event not detected 
by WES
12 8 143956672 CT Insertion Exonic CYP11B1 N394fs*37 Frameshift Damaging CI920932 0 Homo Causal
13 21 45708296 C T SNV Exonic AIRE R203* Stop gain Damaging CM980043 0 Causal
14 21 45708296 C T SNV Exonic AIRE R203* Stop gain Damaging CM980043 0 Causal
15 12 53708169 C T SNV Exonic AAAS W201 Stop gain Damaging 0 Homo Causal
16 12 53701478 A Insertion Exonic AAAS A480fs*16 Frameshift Damaging 0 Homo Causal
17 18 13885094 C A SNV Exonic MC2R V142L Missense Damaging 0 Homo Causal homozygous
18 to 30 No non-synonymous variants found in PAI genes
31 6 32006924 C T SNV Exonic CYP21A2 L86F Missense Tolerated 0 Het ? Causal appears 
het because of 
pseudogene
32 6 32007344 T A SNV Exonic CYP21A2 Y161N Missense Damaging 0 Het ? Causal appears 
het because of 
pseudogene
33 6 32008500 G A SNV Exonic CYP21A2 A392T Missense Tolerated rs202242769/
CM071683
0 Het ? Causal appears 
het because of 
pseudogene
(Continued)
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Patient 
number
chromosome Position 
(genome 
assembly: 
grch37.
p13)
reference 
allele
sample 
allele
Variation 
type
gene 
region
gene symbol Protein variant Translation 
impact
siFT  
function 
prediction
dbsnP iD/
hgMD 
reference 
(where 
annotated)
nhlBi esP 
frequency 
(%)
Zygosity causality
34 No non-synonymous variants found in PAI genes
35 No non-synonymous variants found in PAI genes
36 8 48874189 C T SNV Exonic MCM4 P62S Missense Tolerated 0 Het ? Significance on 
its own
37 18 13885438 G C SNV Exonic MC2R P27R Missense Damaging rs28926178 0.38 Het ? Significance on 
its own
38 8 38003911 G A SNV Exonic STAR R121W Missense Damaging rs34908868 0.12 Het ? Significance on 
its own
38 15 74635368 C T SNV Exonic CYP11A1 E314K Missense Tolerated rs6161 0.28 Het ? Significance on 
its own
39 21 33671389 G C SNV Splice 
Site; 
Intronic
MRAP ? ? No 
translation
Damaging CS050119 0 Het ? Significance on 
its own
40 22 19864750 C A SNV Exonic TXNRD2 A485S Missense Damaging 0 Het ? Significance on 
its own
41 12 53714474 C G SNV Exonic AAAS W42C Missense Tolerated 0 Het ? Significance on 
its own
41 21 33679047 T C SNV Exonic MRAP M68T Missense Activating 0 Het ? Significance on 
its own
42 8 38003911 G A SNV Exonic STAR R121W Missense Damaging rs34908868 0.12 Het ? Significance on 
its own
42 8 48874175 T A SNV Exonic MCM4 V57E Missense Activating 0 Het ? Significance on 
its own
43 5 43616091 C A SNV Exonic NNT L175M Missense Tolerated rs145205428 0.08 Het ? Significance on 
its own
Key: HGMD, Human Gene Mutation Database; EVS, Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA; SNV, single nucleotide variant; PAI, primary adrenal insufficiency; *, stop gain; ?, query.
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(Continued)
TaBle 3 | Variants, including synonymous changes, detected after ingenuity filtration screening of the 20 Pai causal genes listed in Table 1.
Patient 
number
chromo-
some
Position 
(genome 
assembly: 
grch37.
p13)
reference 
allele
sample 
allele
Variation 
type
gene 
region
gene 
symbol
Protein  
variant
Translation 
impact
siFT 
function 
prediction
dbsnP iD/
hgMD 
reference 
(where 
annotated)
nhlBi  
esP 
frequency 
(%)
Zygosity causality Variant 
detected 
with 
second 
pipeline 
analysis 
1 8 48878772 C T SNV Exonic MCM4 S286S Synonymous rs17334388 0.4 Het Not causal het and 
synonymous
Yes
1 8 48882392 A G SNV Exonic MCM4 P403P Synonymous rs17287656 0.38 Het Not causal het and 
synonymous
Yes
1 X 30326991 c a snV exonic nr0B1 e164* stop gain 0 hemi causal Yes
2 X 30326498 g insertion exonic nr0B1 g329fs*60 Frameshift 0 hemi causal Yes
3 8 48878849 C T SNV Exonic MCM4 T312M Missense Tolerated 0 Het Not causal het Yes
3 X 30326727 g a snV exonic nr0B1 Q252* stop gain 0 hemi causal Yes
4 8 143958492 C G SNV Exonic CYP11B1 R181P Missense Damaging rs146105017 0.05 Het ? Significance Yes
4 X 30326343 a insertion exonic nr0B1 Y380fs*9 Frameshift 0 hemi causal Yes
5 8 38006217 C T SNV Exonic STAR L40L Synonymous rs138786388 0.29 Het Not causal het and 
synonymous
Yes
5 15 74631631 g T snV exonic cYP11a1 Q395K Missense Damaging 0 het causal in comp het Yes
5 15 74640307 g a snV exonic cYP11a1 r120Q Missense Damaging 0 causal in comp het Yes
6 15 74635318 c T snV exonic cYP11a1 T330T synonymous splicing 0 het causal in comp het Yes
6 15 74635368 c T snV exonic cYP11a1 e314K Missense Tolerated rs6161 0.28 het causal in comp het Yes
7 15 74630315 a T snV exonic cYP11a1 *122rext*68 stop loss Damaging 0 causal in comp het Yes
7 15 74635473 T Deletion exonic cYP11a1 i279Yfs*9 Frameshift Damaging cD050132 0 causal in comp het Yes
8 15 74630315 a T snV exonic cYP11a1 *122rext*68 stop loss Damaging 0 causal in comp het Yes
8 15 74635473 T Deletion exonic cYP11a1 i279Yfs*9 Frameshift Damaging cD050132 0 causal in comp het Yes
9 12 53708092 A G SNV Exonic AAAS L227L Synonymous rs80027466 0.49 Het Not causal het and 
synonymous
Yes
9 15 74632009 g a snV exonic cYP11a1 a359V Missense Damaging rs121912812 0 homo causal homozygous Yes
10 5 43613069 c T snV exonic nnT r71* stop gain Damaging 0 het causal in comp het 
with pseudoexon 
event not detected 
by Wes
Yes
10 11 2905982 A T SNV Exonic CDKN1C I235I Synonymous 0 Het Not causal het and 
synonymous
Yes
11 5 43613069 c T snV exonic nnT r71* stop gain Damaging 0 het causal in comp het 
with pseudoexon 
event not detected 
by Wes
Yes
11 5 43613188 T G SNV Exonic NNT G110G Synonymous rs200396139 0 Het Not causal het and 
synonymous
No
12 5 43613234 G A SNV Exonic NNT V126I Missense Damaging 0 Het ? Significance Yes
12 5 43700321 A G SNV Exonic NNT I993V Missense Damaging rs78818665 0.43 Het ? Significance Yes
12 8 143956672 cT insertion exonic cYP11B1 n394fs*37 Frameshift Damaging ci920932 0 homo causal Yes
13 21 45708296 c T snV exonic aire r203* stop gain Damaging cM980043 0 causal Yes
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Patient 
number
chromo-
some
Position 
(genome 
assembly: 
grch37.
p13)
reference 
allele
sample 
allele
Variation 
type
gene 
region
gene 
symbol
Protein  
variant
Translation 
impact
siFT 
function 
prediction
dbsnP iD/
hgMD 
reference 
(where 
annotated)
nhlBi  
esP 
frequency 
(%)
Zygosity causality Variant 
detected 
with 
second 
pipeline 
analysis 
14 21 45708296 c T snV exonic aire r203* stop gain Damaging cM980043 0 causal Yes
15 8 48878772 C T SNV Exonic MCM4 S286S Synonymous rs17334388 0.4 Het Not causal het and 
synonymous
Yes
15 8 48882392 A G SNV Exonic MCM4 P403P Synonymous rs17287656 0.38 Het Not causal het and 
synonymous
Yes
15 8 48883160 G A SNV Exonic MCM4 L508L Synonymous 0 Het Not causal het and 
synonymous
Yes
15 8 48885434 TC GA Substitution Exonic MCM4 L649R In-frame Damaging 0 Het Not causal het Yes
15 12 53708169 c T snV exonic aaas W201 stop gain Damaging 0 homo causal Yes
15 15 74631994 T C SNV Exonic CYP11A1 Q364R Missense Tolerated rs57982762 0.02 Het ? Significance Yes
16 12 53701478 a insertion exonic aaas a480fs*16 Frameshift Damaging 0 homo causal Yes
17 18 13885094 c a snV exonic Mc2r V142l Missense Damaging 0 homo causal homozygous Yes
17 22 19868170 G A SNV Exonic TXNRD2 S386F Missense Damaging 0 Het ? Significance Yes
18 to 24
25 5 43613188 T G SNV Exonic NNT G110G Synonymous rs200396139 0 Het Not causal het and 
synonymous
No
26 5 43613188 T G SNV Exonic NNT G110G Synonymous rs200396139 0 Het Not causal het and 
synonymous
No
27 5 43613188 T G SNV Exonic NNT G110G Synonymous rs200396139 0 Het Not causal het and 
synonymous
No
27 9 127262606 G A SNV Exonic NR5A1 Y211Y Synonymous rs374363746 0.13 Het Not causal het and 
synonymous
Yes
28 6 32006337 C A SNV Exonic CYP21A2 P46P Synonymous rs6464 0 Het Not causal het and 
synonymous
Yes
29 8 143960555 G A SNV Exonic CYP11B1 D96D Synonymous rs5284 0.04 Het Not causal het and 
synonymous
Yes
30 18 13885083 G A SNV Exonic MC2R R145R Synonymous rs369830440 0.02 Het Not causal het and 
synonymous
Yes
31 6 32006924 c T snV exonic cYP21a2 l86F Missense Tolerated 0 het ? causal appears 
het because of 
pseudogene
Yes
32 5 43613188 T G SNV Exonic NNT G110G Synonymous rs200396139 0 Het Not causal het and 
synonymous
No
32 6 32007344 T a snV exonic cYP21a2 Y161n Missense Damaging 0 het ? causal appears 
het because of 
pseudogene
Yes
32 22 19868177 C T SNV Exonic TXNRD2 G384S Missense Tolerated rs192869629 0.41 Het ? Causal? comp het Yes
33 5 43613188 T G SNV Exonic NNT G110G Synonymous rs200396139 0 Het Not causal het and 
synonymous
No
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Patient 
number
chromo-
some
Position 
(genome 
assembly: 
grch37.
p13)
reference 
allele
sample 
allele
Variation 
type
gene 
region
gene 
symbol
Protein  
variant
Translation 
impact
siFT 
function 
prediction
dbsnP iD/
hgMD 
reference 
(where 
annotated)
nhlBi  
esP 
frequency 
(%)
Zygosity causality Variant 
detected 
with 
second 
pipeline 
analysis 
33 6 32008500 g a snV exonic cYP21a2 a392T Missense Tolerated rs202242769/
cM071683
0 het ? causal appears 
het because of 
pseudogene
Yes
34 11 2906607 TC AT Substitution Exonic CDKN1C D38I In-frame 0 Het Sequencing anomaly no
35 11 2905964 GG TT Substitution Exonic CDKN1C A241E In-frame 0 Het Sequencing anomaly No
35 11 2905969 CGGG ATCT Substitution Exonic CDKN1C P239_
A240delinsRS
In-frame 0 Het Sequencing anomaly No
36 8 48874189 C T SNV Exonic MCM4 P62S Missense Tolerated 0 Het ? Significance on  
its own
Yes
36 11 2906501 GCCC AGAT Substitution Exonic CDKN1C G62S In-frame Tolerated 0 Het Sequencing anomaly No
36 11 2906509 GCG AGA Substitution Exonic CDKN1C P70L In-frame Damaging 0 Het Sequencing anomaly No
37 9 127245072 GG TC Substitution Exonic NR5A1 N450_
L451delinsKM
In-frame 0 Het Sequencing anomaly No
37 18 13885438 G C SNV Exonic MC2R P27R Missense Damaging rs28926178 0.38 Het ? Significance on  
its own
Yes
38 5 43616018 G T SNV Exonic NNT T150T Synonymous 0 Het Not causal het and 
synonymous
Yes
38 8 38003911 G A SNV Exonic STAR R121W Missense Damaging rs34908868 0.12 Het ? Significance on  
its own
Yes
38 15 74635368 C T SNV Exonic CYP11A1 E314K Missense Tolerated rs6161 0.28 Het ? Significance on  
its own
Yes
39 21 33671389 G C SNV Splice 
Site; 
Intronic
MRAP ? ? No translation Damaging CS050119 0 Het ? Significance on  
its own
Yes
40 22 19864750 C A SNV Exonic TXNRD2 A485S Missense Damaging 0 Het ? Significance on  
its own
Yes
41 12 53714474 C G SNV Exonic AAAS W42C Missense Tolerated 0 Het ? Significance on  
its own
Yes
41 21 33679047 T C SNV Exonic MRAP M68T Missense Activating 0 Het ? Significance on  
its own
Yes
42 8 38003911 G A SNV Exonic STAR R121W Missense Damaging rs34908868 0.12 Het ? Significance on  
its own
Yes
42 8 48874170 T G SNV Exonic MCM4 P55P Synonymous 0 Het ? Significance on  
its own
No
42 8 48874175 T A SNV Exonic MCM4 V57E Missense Activating 0 Het ? Significance on  
its own
No
43 5 43616091 C A SNV Exonic NNT L175M Missense Tolerated rs145205428 0.08 Het ? Significance on  
its own
No
Key: HGMD, Human Gene Mutation Database; EVS, Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA; SNV, single nucleotide variant; PAI, primary adrenal insufficiency.
Variants highlighted in bold are believed to be causal; *, stop gain; ?, query.
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GPX1, HSD3B2, NR5A1, POR, or PRDX3 being detected. 
When rare synonymous variants were included, to encompass 
silent changes that altered splicing (as in patient 6 below), 69 
variants were discovered (Table 3) with no variants in ABCD1, 
CYP17A1, GPX1, HSD3B2, POR, or PRDX3 being detected.
We made a genetic diagnosis in 17 patients plus one affected 
sibling (of patient 9) who did not undergo WES, identify-
ing mutations in the following genes: NR0B1 (four patients), 
CYP11A1 (five patients + one sib), AAAS (two patients), MC2R 
(one patient), CYP11B1 (one patient), AIRE (two patients), and 
NNT (two siblings) (patients 1–17 in Table 2). Where possible, 
segregation of the variant(s) with the disease was confirmed by 
direct Sanger sequencing of the index case and family members.
Patients 1–4, all males, were hemizygous for novel mutations 
in NR0B1, these were stop gain or frameshift mutations and 
therefore likely to be causal. Patients 5–8 had compound het-
erozygous variants in CYP11A1 that segregated with the disease; 
patient 5 was compound heterozygous for two novel missense 
mutations; and patient 6 was compound heterozygous for E314K 
(MAF 0.001%) and a silent T330T variant at the end of exon 5 
of CYP11A1 which we showed, by cDNA analysis, resulted in 
aberrant splicing. Siblings 7 and 8 were compound heterozygous 
for I279Yfs*9, previously reported in lipoid congenital adrenal 
hyperplasia [LCAH; Hiort et al. (29); (29)] and a novel, stop loss 
mutation *122Rext*68. Patient 9 and a sibling had a homozygous 
mutation, A359V in CYP11A1 which has previously been seen in 
LCAH with XY sex reversal (30).
In siblings 10 and 11, we detected a heterozygous stop gain 
mutation, R71* in NNT, no other variants were detected by either 
WES or Sanger sequencing of the other NNT exons; however, the 
presence of a stop mutation on one allele in both siblings prompted 
further investigations including cDNA analysis which uncovered 
a pseudoexon inclusion event on the other allele. A pseudoexon is 
a potential exon within intronic regions of pre-mRNA that is not 
normally spliced into mature mRNA, it contains sequences similar 
to 5′ and 3′ splice-site consensus sequences, but is not normally 
recognized by the cellular splicing machinery. In this case the 
pseudoexon inclusion results in a frameshift and the introduction 
of a premature stop codon (31). Patient 12 had a homozygous 
frameshift mutation in CYP11B1, previously described in CAH 
(32), but also bore novel variants in NNT (see below). Siblings 13 
and 14 were homozygous for a novel, stop gain mutation in AIRE, 
the gene responsible for APECED/APS1. Patients 15 and 16 had 
homozygous stop gain and frameshift mutations, respectively, 
in AAAS, causal for Triple A syndrome. Finally, patient 17 was 
homozygous for a previously described MC2R mutation (33), 
which had been missed on conventional sequencing. In summary, 
for patients 1–17 variants in PAI causal genes were detected which 
were likely to be responsible for their disease.
incidental Mutations in solved cases
Several of the above patients, with a presumed genetic diagnosis, 
bore heterozygous changes in other PAI genes (Table 2); patient 
3 carried p.T312M in MCM4, patient 4 carried p.R181P in 
CYP11B1, patient 12 had three variants, p.L361D in CYP17A1, 
and p.V126I and p.I993V in NNT, patient 15 had two, p.Q364R 
in CYP11A1 and p.L649R in MCM4, and patient 17 had two, 
p.H24_Y25delinsQI in NR5A1 and p.S386F in TXNRD2. The 
contribution of these variants to the burden of their disease is 
uncertain.
no genetic Diagnosis
By contrast, a genetic diagnosis was not confirmed in patients 
18–43. For patients 18–24, no variants were detected in the genes 
screened; patients 25–30 only possessed heterozygous, synony-
mous variants in the 16 genes screened. Patients 31–33 had het-
erozygous changes in CYP21A2 (or its pseudogene/CYP21A1P) 
consistent with gene conversion events but needing further 
investigations to confirm this. Patients 34–43 had heterozygous, 
missense or frameshift variants in genes known to cause PAI, but 
in each case only a single allele was affected. The frameshift vari-
ants found in CDKN1C and NR5A1 in patients 34–37 proved to be 
sequencing anomalies and were excluded by the second analysis 
pipeline, whereas the missense variants in MCM4, MC2R, NNT, 
STAR, CYP11A1, MRAP, TXNRD2, and AAAS seen in patients 
37–43 were confirmed by Sanger sequencing. The G110G and 
L175M NNT variants, the P55P and V57E MCM4 variants, the 
N450_L451delinsKM in NR5A1, and all CDKN1C variants were 
missed by the second analysis (Table 3 last column). A low allele 
fraction for the variant nucleotide accounted for the error in 
calling variants found in NNT and MCM4, but for the changes in 
NR5A1 and CDKN1C the sequence changes were not confirmed 
by Sanger sequencing and on close inspection in Integrative 
Genomics Viewer (IGV, Broad Institute3) were due to misalign-
ment of sequencing reads within repetitive sequences. Sanger 
sequencing of all exons of the affected gene was carried out in 
each case for patients 37–43 to determine whether a causal vari-
ant could be discovered on the other allele but without success. 
The inheritance pattern for these genes is autosomal recessive and 
the causative mutations are loss of function, this would therefore 
suggest that either these are incidental mutations not contribut-
ing to disease, or there are regulatory region or intronic variants 
on the other allele in each of these cases, similar to the scenario in 
NNT for patients 10 and 11. This requires mRNA/cDNA analysis 
for which samples are unavailable at this time.
Discussion
Exome sequencing has been used to successfully identify novel 
variants in diseases causing adrenal insufficiency. In the case of 
FGD, 50% of cases are attributable to mutations in one of three 
genes: MC2R, MRAP, and STAR, which were linked to the dis-
order by traditional linkage and sequencing methods, but with 
the advent of next generation sequencing technologies, three 
further genes have been discovered and more causative genes 
may exist (Figure 1) (14, 17, 18, 28). Targeted exome sequencing 
was used to identify the first variants in NNT and subsequently 21 
variants were identified as causal in FGD (18). In addition, exome 
sequencing was also used to identify the c.71-1insG variant in 
the MCM4 gene which results in the syndrome of adrenal failure, 
short stature, and natural killer (NK) cell deficiency in Irish 
Travelers (17) and the p.Y447* variant in TXNRD2 responsible 
3 https://www.broadinstitute.org/igv/
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for FGD in a large Kashmiri kindred (28). WES provided a rapid 
genetic diagnosis in 17/43 sequenced ‘FGD’ patients, in most 
cases identifying an alternative genetic cause of their PAI (14/17). 
For the remaining 60%, the gene defect may be within intronic/
regulatory regions not covered by WES or may be in gene(s) 
representing novel etiologies.
In the case of suspected PAI, there are many candidate genes 
implicated (Table  1). Exome sequencing offers a rapid, cheap, 
and convenient sequencing technique as the exons of a large 
repertoire of candidate genes can be screened in one sequencing 
run. The findings in this cohort highlight the complex nature of 
adrenal disease and the range of differential diagnoses that may 
arise. It is critical to determine the underlying genetic cause in 
adrenal insufficiency since this may change on-going treatment 
and management. Patients with partial loss-of-function muta-
tions in STAR or CYP11A1 presenting an adrenal-only phenotype 
may have associated fertility problems (14), such patients require 
close monitoring as they may have a window of opportunity for 
fertility that is lost over time. Early genetic counseling should be 
offered to families and discussion about options for preservation 
of fertility is required. Furthermore, the identification of NROB1 
mutations in some of our ‘FGD’ cohort would allow clinicians 
to recognize and manage future issues saving their patients the 
anguish of later unexplained infertility.
Furthermore, adopting exome sequencing as a standard 
screening tool would allow for the identification of variants which 
may have later onset as is the case with the MCM4 variant leading 
to mild cortisol deficiency in childhood which declines with age 
after a period of normal adrenal function (17) or TXNRD2 vari-
ants which may have an extremely variable age of onset (28). Such 
an approach also increases the probability of new gene causality 
being discovered with the accrual of patients without mutations 
in known PAI genes.
There are, however, limitations to exome sequencing as a 
screening tool for known disease gene variants. The exome is 
thought to represent approximately 1% of the human genome, 
thus leaving a large section of the DNA unchecked (34). Although 
the exome is thought to account for 85% of disease causing muta-
tions (25) the true incidence is unknown because of the difficulty 
of sequencing and characterizing intronic variants. Our results, 
both the discovery of a pseudoexon inclusion event and patients 
with single heterozygous changes, suggest the possibility that this 
may occur more frequently than previously recognized (31). For 
patients 10 and 11, the finding of a stop gain mutation in NNT 
in both siblings led us to invest the time to investigate the other 
allele, this detected a pseudoexon inclusion event deep within 
intron 20 (1129 bp from exon 20), a region not covered by WES. 
This might have been missed if it had not been coupled with a 
known deleterious mutation on the other allele or if it had been 
homozygous. Similarly, compound heterozygous intronic muta-
tions would be missed by WES. Whole-genome sequencing would 
disclose such cases but the consequence of such changes can be 
hard to predict. Most significantly, disease causing variants which 
lie in the non-coding promoter and intronic sequence such as is 
the case with apoE4 implicated in Alzheimer’s disease are also not 
detected by exome sequencing (35, 36). In addition, micro RNA 
genes which often silence expression of protein encoding genes 
are often found within introns. The percentage of disease causing 
mutations in exonic sequences may decrease with the application 
of whole-genome sequencing in patients and the improvement of 
tools for consequence prediction.
Even when dealing with an exonic variant the prediction of its 
pathogenicity is not trivial and this is exacerbated when the vari-
ant is outside coding sequences. Many computational methods 
have been developed to address this but concordance between 
the results generated by such programs is poor (37). Therefore, for 
optimal assessment of a variants effect more than one prediction 
program should be utilized and, where possible, functional stud-
ies should be undertaken. Similarly, multiple software tools for 
alignment and variant calling are available, and each can generate 
different results, here again it is recommended that more than 
one algorithm be employed when analyzing exome data (38, 
39). Particularly low concordance rates have been reported for 
INDELs detected by different pipelines and sequencing platforms 
(40, 41) stressing the need to carry out multiple analyses on 
data sets. Depth of coverage is also a consideration, at a mean 
on-target read depth of 20X, commonly achieved in rare disease 
exome sequencing, it is predicted that 5–15% of heterozygous and 
1–4% of homozygous single nucleotide variants (SNVs) in the 
targeted regions will be missed (42). Sulonen et al. showed that a 
minimum of 11X coverage was required to make a heterozygote 
genotype call with 99% accuracy, whereas homozygous calls can 
be accurate at much lower coverage (43).
Our exome data, ordered at a depth of 30X for economy, has 
many exons which are not covered 30X. For new gene discovery, 
this depth of coverage may be sufficient but it is clearly not ideal 
for diagnosis where a more appropriate depth might be 100X. 
One way to increase depth of coverage is to use a custom enrich-
ment panel to go forward for next-generation sequencing. Many 
companies are now introducing clinical exome panels designed 
to capture the exons of disease causing genes, e.g., OneSeq and 
SureSelectXT Clinical Research Exome (Agilent) which may 
concomitantly detect genome-wide CNVs, copy-neutral LOH 
(cnLOH), SNPs, and indels in one target enrichment capture.
Additional disadvantages of WES include the fact that it can-
not detect epigenetic changes, or mutations that do not alter the 
sequence, for instance, translocations, inversions, and repeats 
such as in Huntington’s disease. Consequently, exome sequenc-
ing cannot easily be used to assess gene copy number dependent 
disease susceptibility, as non-sequence alteration changes are not 
recognized. However, algorithms to address this have been and 
are being developed (44–46) and this is important as variations in 
copy number can affect the severity or susceptibility to a disease. 
Furthermore, silent changes, which may not affect amino acid 
sequence but alter splicing either directly or by alteration of splice 
enhancer/repressor sites, may be ignored as they are excluded 
from analysis by common filtration strategies. Difficulties also 
arise in WES in distinguishing between genes with extremely 
similar nucleotide sequences, where a gene possesses a paralog 
or pseudogene(s) with very similar sequence. For PAI, there are at 
least two such complications; to differentiate between CYP21A2 
and its pseudogene CYP21A1P and distinguishing between the 
paralogs CYP11B1 and CYP11B2. This is usually achieved by PCR 
amplification strategies using primers spanning the distinguishing 
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